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Tha pnnercntk P-ccl1 hormone umylin tictrl in is&ted rat ~kclctt41 rnuv& te dccrcarc innulin4rimulatcd ineorpatrrtiun aT ~iuc~rir into gtlyerrgcn, 
ft alat, inerrrrrcn blood Icvci~ of lnetntc and yluease in fart& rats in viva, klowever, it rcmnirxd unecrktin whcthcr rmylin cxcrts diraet cfkcetjl to 
atimul#te mur;elc glyeqcnolywia. Wc now report that amylin cuu~rd a darc&pcndcnt incrctlzc in rtetlviry sf murcle glyeagcn phawpharykc in 
irulrtcd rat sulcus muxlc by xtlmulating phadphsrylrse tt. Inxulia inhibited umylin-stimulated tlctiwttion rrf phu~pharylslc. Efikta d amylin to 
atimuhitc mu~clc giyeagcnolyrix tire een&xcnt with abacrvctl ctktw t>f umylin in viva and could bc P majar mcehtminm wkcrrby amylin mudulatcr 
earbohydrrrc mctubolism, 
Amylin: M~lc; Gt)cogcn: Phaspheryluxc 
1. INTRODUCTION blood concentrations of lactate and glucose in 18-h 
Fasted rats [L2j. 
Amylin is the major protein component of islet 
amyloid commonly found in the pancreases of patients 
with non-insulin-dependent diabetes mellitus [1,2], It is 
expressed primarily in islet &cells and secreted from the 
pancreas following stimulation by nutrients such as 
ylucosc or arginine 131, Several studies have 
demonstrated that amylin has properties which support 
the concept hat it modulates carbohydrate metabolism 
[2,4-121. 
In vitro studies have shown that amylin can act on 
skeletal muscle to decrease rates of glucose uptake and 
incorporation into glycogen [4-g], Homologous 
calcitonin gene-related pcptide (CGRP) also inhibits net 
glycogen synthesis in white (extensor digitorum longus) 
muscles and to a lesser extent in red (soleus) muscles 
[5,6]. Some studies have proposed that amylin increases 
glycogenolysis, reduces glycogen content and increases 
lactate production. However, it has also been proposed 
that the data might be explained by inhibition of 
glycogen synthesis [9] and one recent report stated that 
amylin does not promote muscle glycogen breakdown 
or enhance lactate production in the presence of insulin 
[7]. In vivo studies using euglycemic, hyperinsulinemic 
glucose clamps in rats have shown that amylin decreases 
insulin-mediated suppression of hepatic glucose output 
[lo,1 11, and peripheral uptake of glucose [9-l 13. 
Recently, we have shown that amylin acts to increase 
Glycogcn is the major storage form of carbohydrate 
in muscle cells. While some of the previous results using 
isolated muscle might have been explained by stimula- 
tion of glycogenolysis, no biochemical mechanism has 
been identified, In the experiments reported here, we 
measured the activity of phosphorylase, the rate- 
limiting enzyme of glycogenolysis, in extracts from rat 
soleus muscles incubated with different concentrations 
of rat amylin, and in the presence and absence of 7,l 
nM insulin, The phosphorylase assay conditions are 
designed to minimize the activity of phosphorylase b
and thus to selectively measure the ac!ivity of 
phosphorylase n, the phosphorylated enzyme form that 
results from the action of phosphorylase kinase on 
phosphorylase. 
2. MATERIALS AND METHODS 
2.1,1+ Animals 
Harlan Sprague-Dawlcy rats (200 g males), were housed at 
22.7 L+ 0,8”C in a 12: 12 hour light/dark cycle (experiments being per- 
formed during the light cycle) and fed and watered ad libitum (Diet 
LM-485, Teklad, Madison, WI). Animals were fasted for 4 h before 
experimentation. 
2.1.2. Amylin 
Corrquc?ndei?ce uddr ss: B.A. Young, Department of Physiology, 
Amylin L’orporation, 9313 Towne Centre Drive, Ste. 250, San Diego, 
CA 92121, USA. Fax: (1) (619) 552 2212 
Amylin requires the presence within the molecule of both an intact 
intramolecular Cysz-Cys’ disulfide bond and a carboxy-terminal 
amide group to exert full biological activity to reduce incorporation 
of ‘JC-labelled glucose into skeletal muscle glycogen [13]. 
Bioactivity of commercially available preparations of amylin, as 
measured by the E&O for inhibition of net insulin-stimulated 
Published by Elsevier Science Publishers B. V. 
1.1.3. Chzmicntr 
Ssiubic Insulin, (E~umuiin R, 1863 W/ml) WHS pureharctl from Eli 
Lilly nnd Co., Irrdinnapulin, IN. The cunvcrtlsn ~‘DC’IW between w 
llvily unilr, L), anti muiirr iniils r(dp inrniin uxed in iire ~mxenr xturly 
wad I pUJm1 a 7, I pkl. Ail alirw Ni~~CIllt wcrc: tJr nnaiylisal tjrxle 
or bfner unisxr oihrrwlse xrz~icd. 
lxuin~ian and incubation of i~aia~erl, rrtipprtl 1:~ soirux milr;dcx in 
rhr prarncrsf vurioils conccnrrn~ionx of insulin anti amyiin were per. 
formcd ascarding IO prcviou$iy dcscribcd mc0rotis [J,Sl. Four ~nnxcie 
strips were incubntcd at each lrcalincnl condition. 
Can~ral incubndonx wcrc pcrformcrl in the nbscriec or prcacncc 0r 
inxulin (7. I nM) or amyiin (34 nM). Rorc-dcpcndcrn effects ofnmyiirr 
on giycogen phewphoryia~~ (I acrivily were s[udicd in rhc prcsrncc of 
eonstnnl inxuiili (7.1 nM), at incrcaaing canccnlmtion~ al nmylin (0, 
0.39, 3,9, 76, 781 nkl). 
After incubalion, murcics wcresnspWfroxcn In liquid nitropcn, lhcn 
storcn at - 70°C until nicnsurcmcnt5 or &xovx~ phosphorylnsc ff ne 
tlvity were made. 
Activity af glycoycn phosphorylxic CI in muscle cxtrncta was dclcr- 
mined using a previously described modified method [IS] omitting 
AMP in the assay ~a mcnsurc phosphorylasc II. Enzyme activity is cx- 
pressed as nmol * glucosyi units transfcrrcd/min/mg prolciii. Con- 
ccntrafions of protein in munclc tissue cxtriicts were measured ac- 
cording to the method af Bradford (161. 
Ail results are present4 as mean & SE. Statistical analysis was per. 
formed using the non-paired, two-tailed Student’s r-test, with 
significance levels as stated. 
3. RESULTS AND DISCUSSION 
Treatment of isolated rat skeletal muscle with 34 nM 
amylin in the absence of insulin increased the activity of 
muscle glycogen phosphorylase u by 2.8.fold, from a 
basal level of 8.5 -I 0.8 nmol . glucosyl units/min/mg 
protein to 23.7 k 4.1 nmol - glucosyl units/min/mg 
protein (P c 0.0001) (Fig. 1). 
Amylin produced a dose-dependent increase in the 
activity of piycogen phosphorylase a in the presence of 
7.1 nM insulin (Fig. 2). Enzyme activity increased 
2.7-fold from a basal evel of 6.8 f 0.7 nmol * glucosyl 
units/min/mg protein in the absence of amylin to 18.1 
AZ 2.9 nmol - glucosyl units/min/mg protein at an 
amylin concentration of 76 nM (P c 0.0001). 
In the absence of amylin, 7.1 nM insulin did not. pro= 
duce a significant change in glycogen phosphorylase a 
activity (Fig. 1). This is consistent with in vivo 
dose-response studies in humans where we failed to 
show an inhibition by insulin of already low glycogen 
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Fig. I. Pkcspharyleac asliviry w,rErh nmyiin and inxuiin. Giycta#en 
phorphoryln~ca in IRC ixaiarctl roierrs mu~clr! afrrr I h incubaion wirh 
insulin alunc (7.1 nM), rin nmylin alone, (34 nki) or inxniin (7, I nM) 
plus rat amylin (76 Ml, lfars rrrprclienl man * SE, Ii = 4 a1 rarh 
point. 
pkosphorylasc activity [17], On the other hand, in the 
presence of amylin, insulin significantly decreased 
glyeogen phosphorylase Nactivity: at 34 nM amylin in 
the absence of insulin, enzyme activity was 23,7 f 4.1 
nmol - glucosyl units/min/mg protein, while at an in- 
sulin concentration of 7,l nM, phosphorylase o activity 
in the presence of 76 nM amylin fell to 9.4 1 1.0 
nmol . glucosyl units/min/mg protein (P < 0,02 com- 
pared with activity at 34 nM amylin), We are unaware 
of any reports demonstrating insulin inhibition of 
glycogen phosphorylase activity in muscle, although 
Amyiin (nhrij 
Fig. 2. Phosphorylase/amylin dose-response. Clycogen phosphor- 
ylase n activity in the isolated soleus muscle following 1 h incubation 
with increasing concentrations of amylin in the presence of 7.1 nM 
insulin, Bars represent means f SE, n=4 at each point. 
such an et%et had bsen prardictcd by rht: abaervntisn 
rtwt insulin c’wwex dc~t~~~phar~~~G~~n af IN sngyme 
I]@]. ~i~nirica~Gl~~ innul,in t?nn inhibir rhc emylin- 
mrdicated activaritln aF pho~ph~~~l~~e~ while Ghc $I- 
ndrener& fl9’) acrivarion or rhc enzyme wax nat in- 
hibited by insulin WG conernlfalilanr cquivalenr 16 Ghoae 
used in Gh’e present #Gudy [20]. 
Glycogen phe)sphorylasc is Ghe rr\Gr-limiting ensryme 
in $l~~~~~n~l~~i~ [21], Thi$ snnymc eutrrlyacs Ghc xc- 
quenrial phoaphorolyais of ar-Cl-34).linked glueosyl 
unira feom Ghc non-reducing end of &wgen strands to 
form glucoxe~I=phosplrflrc. Phoophorylnse exists in Gwo 
inrercsnverliblc forms, PI and Q. Phosphsrylasc 0, the 
fesring form in muscle, is an b8 dimer aP M, 2 x 97 506 
Da. This form is innerivc, but is actiwtcd by the 
albtwic efftXGaP$ AMP and IMP, whereas ATP and 
ADP GICG 8% alloareric inhibirors [21). PhoYpkOfylarc u 
aelivity, as mrwred in Gllc pfcs@nG study, is GhaG which 
is associated wirh the pkosphorylnted form of Ghc en- 
zyine fine! is assayed in the absence of AMP Go minimize 
Rctivicy of ptrosphofylnxe b. 
In response 10 hormonal or neural signals, 
phosphorylase b is converted Go phosghorylase n by 
phosphorylarion of Scr”, caralyzcd by phosphorylase 
kinase, Phosphorylasc it is fully active at saturating 
substrate concentrations, buG at low concenrrations of
Pi its activiry is stimulated by AMP. Glucose is an 
allosteric inhibitor of this enzyme [21]. 
The ability of amylin to produce dose-dependent i -
creases in the activity of phosphorylasc in skeletal mus- 
cle in vitro suggests that amylin probably stimulates 
phosphorylation of the enzyme to effect conversion of 
the b to the u form. 
In order to activate phosphorylase, amylin 
presumably acts through an as yet unidentified signalt- 
ing pathway, in which the first event is binding of 
amylin to an amylin receptor. Since amylin and CGKP 
stimulate adenylate cyclase in liver membranes and 
CGRP increases CAMP levels in skeletal muscle 
[22-241, one possible mechanism is that the amylin 
receptors in muscle are linked via Cs to adenylate 
cyclase, and that activation of phosphorylase iscaused 
by CAMP-dependent protein kinase-mediated activa- 
tion of phosphorylase kinase, Because amylin-mediated 
activation was insulin-inhibitable, while adrenalin- 
mediated activation was not, it is clear that these two 
hormones cannot induce phosphorylase activation 
through identical mechanisms. 
The effect of amylin to stimulate phosphorylase u ac- 
tivity seen in our present study provides a molecular 
mechanism whereby amylin could exert previously 
observed biological effects. Stimulation of 
phosphorylase activity in skeletal muscle, leading to in- 
creased rates of glycogenolysis and glycolysis, could ac- 
count for dose-dependent i creases in plasma lactate 
produced by amylin [Young, AA. et al. in prepara- 
Con]. Amylin stimulation of phosphorylase activity 
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